NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 646,111 shares of the medical research company's stock after purchasing an additional 42,895 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.50% of NeoGenomics worth $10,648,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in NeoGenomics in the fourth quarter worth $26,000. Sterling Capital Management LLC boosted its holdings in shares of NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after buying an additional 3,289 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of NeoGenomics by 203.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after buying an additional 2,787 shares during the period. Blue Trust Inc. increased its stake in shares of NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after acquiring an additional 1,103 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of NeoGenomics by 44.7% in the 4th quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock worth $108,000 after acquiring an additional 2,027 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Stock Performance

Shares of NEO traded down $0.10 during trading hours on Wednesday, hitting $7.38. The stock had a trading volume of 1,561,345 shares, compared to its average volume of 1,175,057. The firm has a market capitalization of $949.77 million, a PE ratio of -11.90 and a beta of 1.60. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. NeoGenomics, Inc. has a 12 month low of $6.08 and a 12 month high of $19.12. The stock has a fifty day moving average price of $8.41 and a 200 day moving average price of $12.21.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $168.04 million for the quarter, compared to the consensus estimate of $171.38 million. During the same period in the prior year, the business earned ($0.02) earnings per share. NeoGenomics's revenue was up 7.6% compared to the same quarter last year. Analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Insider Activity at NeoGenomics

In related news, CEO Anthony P. Zook purchased 18,900 shares of NeoGenomics stock in a transaction dated Tuesday, May 6th. The stock was purchased at an average cost of $7.88 per share, with a total value of $148,932.00. Following the transaction, the chief executive officer now owns 18,900 shares in the company, valued at approximately $148,932. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Warren Stone purchased 5,700 shares of the business's stock in a transaction on Monday, May 12th. The stock was purchased at an average cost of $8.58 per share, for a total transaction of $48,906.00. Following the completion of the acquisition, the chief operating officer now directly owns 108,280 shares of the company's stock, valued at approximately $929,042.40. The trade was a 5.56% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 70,600 shares of company stock worth $550,438. Company insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on NEO. Wall Street Zen raised shares of NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group dropped their target price on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Needham & Company LLC lowered their price objective on NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Piper Sandler set a $12.00 target price on NeoGenomics and gave the stock an "overweight" rating in a report on Tuesday, May 6th. Finally, Leerink Partners cut NeoGenomics from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $25.00 to $9.00 in a research note on Wednesday, April 30th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $13.83.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.